59
Participants
Start Date
August 9, 2023
Primary Completion Date
December 30, 2026
Study Completion Date
December 30, 2026
ARV-471 (PF-07850327)
Pharmaceutical form: Tablets. Route of Administration: Oral
Palbociclib
Pharmaceutical form: Capsules. Route of Administration: Oral.
Letrozole
Pharmaceutical form: Capsules. Route of Administration: Orally
Palbociclib
Pharmaceutical form: Capsules. Route of Administration: Oral.
Barwon Health, Geelong
Cancer Research SA, Adelaide
Tumor Zentrum Aarau, Aarau
Hospital Unviersitario Virgen Nieves, Granada
Fondazione IRCCS San Gerardo dei Tintori, Monza
Complejo Hospitalario de Jaén, Jaén
Virginia Oncology Associates, Norfolk
Hospital Clinico San Carlos, Madrid
Hospital Universitario Virgen de la Victoria, Málaga
BRCR Medical Center Inc, Plantation
"IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori", Meldola
Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli
Nemocnica na okraji mesta n o, Partizánske
Cancer Hospital Chinese Academy of Medical Science, Beijing
Hubei Cancer Hospital, Wuhan
Sun Yat-sen University Cancer Center, Guangzhou
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Hospital Santa Rita de Cassia, Vitória
Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa, Porto Alegre
Centro de Pesquisa Clínica - Área Administrativa, Porto Alegre
Hospital Mae de Deus, Porto Alegre
Debreceni Egyetem Klinikai Kozpont, Debrecen
Aichi Cancer Center Hospital, Nagoya
National Cancer Center Hospital East, Kashiwa
National Cancer Center Hospital, Chuo-ku
Fakultna nemocnica s poliklinikou J.A. Reimana Presov, Prešov
Institut Català d'Oncologia (ICO) - Badalona, Badalona
Hospital Universitari Dexeus, Barcelona
Lead Sponsor
Arvinas Estrogen Receptor, Inc.
INDUSTRY
Pfizer
INDUSTRY